NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$168.90
+0.51 (+0.30 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$167.40
Now: $168.90
$170.16
50-Day Range
$160.45
MA: $166.19
$173.15
52-Week Range
$101.81
Now: $168.90
$178.64
Volume512,738 shs
Average Volume719,861 shs
Market Capitalization$9.51 billion
P/E Ratio53.28
Dividend YieldN/A
Beta1.08
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone(531) 634-7800
Employees1,940
Year Founded2003

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$23.01 per share
Book Value$54.99 per share

Profitability

Net Income$523.37 million

Miscellaneous

Market Cap$9.51 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

Headlines

Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $176.00
April 1, 2021 |  americanbankingnews.com
Samantha Gleit – Behind Debt Structure In Today's Cannabis Industry
March 23, 2021 |  markets.businessinsider.com
Recap: Jazz Pharmaceuticals Q4 Earnings
February 24, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

39th out of 2,025 stocks

Pharmaceutical Preparations Industry

17th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$168.90
+0.51 (+0.30 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Jazz Pharmaceuticals?

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Jazz Pharmaceuticals
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings results on Tuesday, February, 23rd. The specialty pharmaceutical company reported $4.00 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.58 by $0.42. The specialty pharmaceutical company had revenue of $665.52 million for the quarter, compared to analysts' expectations of $639.83 million. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 20.16% and a net margin of 7.86%. Jazz Pharmaceuticals's revenue was up 14.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.42 earnings per share.
View Jazz Pharmaceuticals' earnings history
.

How has Jazz Pharmaceuticals' stock been impacted by COVID-19?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 56.3% and is now trading at $168.90.
View which stocks have been most impacted by COVID-19
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided earnings per share guidance of 15.65-16.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.78. The company issued revenue guidance of $2.55-2.7 billion, compared to the consensus revenue estimate of $2.56 billion.

What price target have analysts set for JAZZ?

18 brokers have issued 12-month target prices for Jazz Pharmaceuticals' shares. Their forecasts range from $128.00 to $233.00. On average, they expect Jazz Pharmaceuticals' share price to reach $186.78 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Bruce C. Cozadd, Chairman & Chief Executive Officer (LinkedIn Profile)
  • Daniel N. Swisher, President & Chief Operating Officer
  • Renée D. Galá, Chief Financial Officer & Executive Vice President
  • Robert Iannone, Chief Medical Officer, EVP-Research & Development
  • Finbar Larkin, Senior Vice President-Technical Operations

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Retirement Systems of Alabama (0.24%), Cardan Capital Partners LLC (0.04%), Louisiana State Employees Retirement System (0.03%), Centric Wealth Management (0.02%), State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals
.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, AdvisorNet Financial Inc, Confluence Investment Management LLC, Veriti Management LLC, and Centric Wealth Management. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Finbar Larkin, Patricia Carr, Patrick G Enright, and Paul L Berns.
View insider buying and selling activity for Jazz Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, TrimTabs Asset Management LLC, Louisiana State Employees Retirement System, Cardan Capital Partners LLC, Pacer Advisors Inc., and Crossmark Global Holdings Inc..
View insider buying and selling activity for Jazz Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $168.90.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $9.51 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 1,940 workers across the globe.

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Where are Jazz Pharmaceuticals' headquarters?

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.